News

Mirati Therapeutics Reports First Quarter 2017 Financial Results

SAN DIEGO, May 4, 2017 /PRNewswire/ — Mirati Therapeutics, Inc. (MRTX), a clinical stage oncology biotechnology company, reported financial results for the first quarter 2017 and provided an update on its product development programs.

2017-06-21T10:44:55+00:00